MediGene AG Announces Change to Supervisory Board

Martinsried/Munich, October 31, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) announces that Dr. Thomas Strüngmann, Managing Director of Santo Holding (Germany) GmbH, will resign from his role as a Supervisory Board member of MediGene AG for personal reasons, effective from January 1, 2009.

Prof. Dr. Ernst-Ludwig Winnacker, Chairman of MediGene's Supervisory Board commented: "We very much regret the fact that Dr. Strüngmann has resigned from office. He showed great commitment on our Supervisory Board, and through his expertise he contributed significantly to the refocusing of our company's strategy. On behalf of both our Supervisory and Executive Boards, I would like to express my heartfelt thanks to him."

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® is a registered trademark of MediGene AG. This trademark may be owned or licensed in select locations only.

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, two of which providing a very high sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.

Back to news